Curanex Pharmaceuticals Inc (CURX): R&D Expense
$2.99M
Year ended 2025-12-31
$9.11M
Trailing 12 months to 2026-09-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.99M | n/a | 2026-03-30, From 2025-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Curanex Pharmaceuticals Inc (CURX) | 2025-12-31 | $2.99M | n/a |
| Revelation Biosciences, Inc. (REVB) | 2025-12-31 | $4.06M | +14.5% |
| NewcelX Ltd. (NCEL) | 2025-12-31 | $1.13M | +13.5% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $1.14M | -90.3% |
| MetaVia Inc. (MTVA) | 2025-12-31 | $6.80M | -68.4% |
| Mira Pharmaceuticals, Inc. (MIRA) | 2025-12-31 | $1.72M | -48.0% |
| Decoy Therapeutics Inc. (DCOY) | 2025-12-31 | $368.2K | -52.2% |
| Lantern Pharma Inc. (LTRN) | 2025-12-31 | $11.51M | -28.6% |
| Turn Therapeutics Inc. (TTRX) | 2025-12-31 | $265.6K | +8.0% |
Compare CURX, REVB, NCEL, PRFX side by side · Screen every company in Pharmaceutical Preparations ↗